Opus Genetics, Inc. (IRD)
NASDAQ: IRD · Real-Time Price · USD
1.070
-0.040 (-3.59%)
Aug 1, 2025, 11:04 AM - Market open
Opus Genetics Revenue
Opus Genetics had revenue of $4.37M in the quarter ending March 31, 2025, with 155.41% growth. This brings the company's revenue in the last twelve months to $13.65M, down -28.19% year-over-year. In the year 2024, Opus Genetics had annual revenue of $10.99M, down -42.30%.
Revenue (ttm)
$13.65M
Revenue Growth
-28.19%
P/S Ratio
2.36
Revenue / Employee
$758,389
Employees
18
Market Cap
63.84M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 10.99M | -8.06M | -42.30% |
Dec 31, 2023 | 19.05M | -20.80M | -52.20% |
Dec 31, 2022 | 39.85M | 39.26M | 6,665.70% |
Dec 31, 2021 | 589.00K | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 57.37B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
IRD News
- 9 days ago - Opus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood Blindness - GlobeNewsWire
- 4 weeks ago - Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia - GlobeNewsWire
- 5 weeks ago - Opus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK Program - GlobeNewsWire
- 2 months ago - Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions - GlobeNewsWire
- 2 months ago - Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Opus Genetics Announces Presentations on Inherited Retinal Disease Programs at Medical Conferences in May - GlobeNewsWire
- 3 months ago - Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy Candidate - GlobeNewsWire